• Australian Clinical Labs Limited


  • Healius Limited


Australian Clinical Labs Limited (ACL) is seeking to acquire Healius Limited (Healius) by way of an off-market takeover offer to acquire all the fully paid ordinary shares in Healius.

ACL and Healius provide human pathology services to out-patients, in-patients (at public and private hospitals), and commercial and government customers, as well as veterinary pathology services. Healius also provides diagnostic imaging services.

Market inquiries

The ACCC has commenced market consultation on the proposed undertaking.

The ACCC invites submissions on the proposed undertaking by 17 October 2023. Submissions should be forwarded electronically (preferably in PDF format) to with the title “Submission re: ACL/Healius – Proposed Undertaking – attention Annelise Caplan/Aggie Marek”.

Following this date, queries regarding the ACCC’s review may be addressed to Annelise Caplan/Aggie Marek at

For more details, please refer to the undertaking consultation letter below


Date Event

ACCC commenced review under the Merger Process Guidelines.

Closing date for submissions.

Former provisional date for announcement of ACCC’s findings (22 June) delayed at ACL’s request. ACCC will announce a revised provisional decision date in due course. 

ACCC received further information from ACL. Timeline recommenced. 

ACCC published a Statement of Issues outlining preliminary competition concerns.

Closing date for submissions relating to Statement of Issues.

Timeline suspended pending receipt of further information.  Former proposed decision date for announcement of ACCC's findings (12 October 2023) is delayed.

ACCC commenced market consultation on proposed s87B undertaking. 

Closing date for submissions relating to the proposed s87B undertaking.

ACCC received further information. Timeline recommenced. 

Proposed date for announcement of ACCC’s decision.

Project staff

  • Claudia Gulbransen-Diaz
  • Debbie Ravalli

Contact email